Atorvastatin 10 mg daily significantly reduced the occurrence of primary end-point of MACE and secondary end-points of CHD events, coronary revascularizations and stroke during a median follow-up of 3.9 years in 2838 patients with type 2 diabetes and LDL < 160 mg/dL. Trial was stopped 2 years earlier than expected.
CARDS
Bubo
STEMI
Brain fag syndrome
Near drowning
Spinal shock
Electric shock
COACH syndrome